latest update:
[TrialBase DB]

trial summary · NCT07197671

Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer

Phase 1 Study of Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 Therapy for Metastatic Cancer

Trial record from the TrialBase DB dataset, status RECRUITING, condition Metastatic Cancer, sponsored by University of Wisconsin, Madison. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07197671phase PHASE1enrollment 60start 2026-11-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enrolled and can expect to be on study for up to 9 months.

Source record: https://clinicaltrials.gov/study/NCT07197671

Facts

registry idNCT07197671
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionMetastatic Cancer
sponsorUniversity of Wisconsin, Madison
sponsor classOTHER
enrollment60
start date2026-11-01
primary completion2028-09
completion2028-09
results postednot reported

Conditions

  • Metastatic Cancer

Interventions

  • 90Y-NM600

Countries

  • United States

Intervention types: DRUG

Work with this record